Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) Enterprise Value (2016 - 2026)

Pharma-Bio Serv filings provide 17 years of Enterprise Value readings, the most recent being -$10.6 million for Q1 2026.

  • On a quarterly basis, Enterprise Value rose 15.07% to -$10.6 million in Q1 2026 year-over-year; TTM through Jan 2026 was -$10.6 million, a 15.07% increase, with the full-year FY2025 number at -$10.9 million, up 14.84% from a year prior.
  • Enterprise Value hit -$10.6 million in Q1 2026 for Pharma-Bio Serv, up from -$10.9 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$10.4 million in Q2 2025 to a low of -$15.9 million in Q1 2024.
  • Median Enterprise Value over the past 5 years was -$13.5 million (2024), compared with a mean of -$13.3 million.
  • Biggest five-year swings in Enterprise Value: dropped 3.56% in 2023 and later rose 22.75% in 2025.
  • Pharma-Bio Serv's Enterprise Value stood at -$14.5 million in 2022, then dropped by 3.56% to -$15.0 million in 2023, then increased by 14.9% to -$12.7 million in 2024, then rose by 14.84% to -$10.9 million in 2025, then grew by 2.71% to -$10.6 million in 2026.
  • The last three reported values for Enterprise Value were -$10.6 million (Q1 2026), -$10.9 million (Q4 2025), and -$10.7 million (Q3 2025) per Business Quant data.